The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
14
02
2024
received:
18
12
2023
accepted:
25
02
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
ppublish
Résumé
This study evaluated and characterized the pharmacological activity of the orally administered interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors BAY1834845 (zabedosertib) and BAY1830839 in healthy male volunteers. Participants received one of either IRAK4 inhibitors or a control treatment (prednisolone 20 mg or placebo) twice daily for 7 days. Localized skin inflammation was induced by topical application of imiquimod (IMQ) cream for 3 days, starting at Day 3 of treatment. The inflammatory response was evaluated by laser speckle contrast imaging (skin perfusion) and multispectral imaging (erythema). At Day 7, participants received 1 ng/kg intravenous lipopolysaccharide (LPS). Circulating inflammatory proteins, leukocyte differentiation, acute phase proteins, and clinical parameters were evaluated before and after the systemic LPS challenge. Treatment with BAY1834845 significantly reduced the mean IMQ-induced skin perfusion response (geometric mean ratio [GMR] vs. placebo: 0.69 for BAY1834845, 0.70 for prednisolone; both p < 0.05). Treatment with BAY1834845 and BAY1830839 significantly reduced IMQ-induced erythema (GMR vs. placebo: 0.75 and 0.83, respectively, both p < 0.05; 0.86 for prednisolone, not significant). Both IRAK4 inhibitors significantly suppressed the serum TNF-α and IL-6 responses (≥80% suppression vs. placebo, p < 0.05) and inhibited C-reactive protein, procalcitonin, and IL-8 responses to intravenous LPS. This study demonstrated the pharmacological effectiveness of BAY1834845 and BAY1830839 in suppressing systemically and locally induced inflammatory responses in the same range as prednisolone, underlining the potential value of these IRAK4 inhibitors as future therapies for dermatological or other immune-mediated inflammatory diseases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13771Subventions
Organisme : Bayer AG
Informations de copyright
© 2024 Bayer AG and Centre for Human Drug Research. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Kelly PN, Romero DL, Yang Y, et al. Selective interleukin‐1 receptor‐associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212(13):2189‐2201.
Chaudhary D, Geddes B, Robinson S, et al. Identification of highly potent and selective interleukin‐1 receptor‐associated kinase 4 inhibitors for the treatment of rheumatic diseases. Poster presented at 76th annual meeting of the American College of Rheumatology. Arthritis Rheum. 2012;64:S459.
Danto S, Shojaee N, Singh R, et al. Efficacy and safety of the selective interleukin‐1 receptor associated kinase 4 inhibitor, PF‐06650833, in patients with active rheumatoid arthritis and inadequate response to methotrexate. Arthritis Rheum. 2019;71(Suppl. 10):2909. Accessed May 25, 2022. https://acrabstracts.org/abstract/efficacy‐and‐safety‐of‐the‐selective‐interleukin‐1‐receptor‐associated‐kinase‐4‐inhibitor‐pf‐06650833‐in‐patients‐with‐active‐rheumatoid‐arthritis‐and‐inadequate‐response‐to‐methotrexate/
ClinicalTrials.gov NCT04772885. A single and multiple ascending dose trial of KT‐474 in healthy adult volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). 2021. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT04772885
ClinicalTrials.gov NCT05178342. Treatment of anemia in patients with very low, low or intermediate risk myelodysplastic syndromes with CA‐4948 (LUCAS). 2022. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT05178342
ClinicalTrials.gov NCT05380934. A clinical trial of safety and tolerance of TQH3821 tablets in adult healthy subjects. 2022. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT05380934
Bothe U, Günther J, Nubbemeyer R, et al. Discovery of IRAK4 inhibitors BAY1834845 (zabedosertib) and BAY1830839. J Med Chem. 2024;67(2):1225‐1242.
van der Kolk T, Assil S, Rijneveld R, et al. Comprehensive, multimodal characterization of an imiquimod‐induced human skin inflammation model for drug development. Clin Transl Sci. 2018;11(6):607‐615.
van Poelgeest EP, Dillingh MR, de Kam M, et al. Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. J Pharmacol Toxicol Methods. 2018;89:39‐46.
Niemeyer‐van der Kolk T, Assil S, Buters TP, et al. Omiganan enhances imiquimod‐induced inflammatory responses in skin of healthy volunteers. Clin Transl Sci. 2020;13(3):573‐579.
Monnet E, Lapeyre G, Poelgeest EV, et al. Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. Clin Pharmacol Ther. 2017;101(2):200‐208.
ClinicalTrials.gov NCT03054402. First in human study to investigate the safety, tolerability, pharmacokinetics and to explore pharmacodynamics of BAY1834845. 2017. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT03054402
ClinicalTrials.gov NCT03493269. A multiple dose study of BAY1834845 in healthy male subjects and in patients with psoriasis. 2018. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT03493269
ClinicalTrials.gov NCT03540615. BAY1830839: first in man, single dose escalation, safety & tolerability and pharmacokinetics. 2018. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT03540615
ClinicalTrials.gov NCT03965728. Study to investigate safety, tolerability, pharmacokinetics, and drug–drug interaction of multiple oral doses of BAY1830839 in healthy male participants. 2019. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT03965728
Fowler J, Jarratt M, Moore A, et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. Br J Dermatol. 2012;166(3):633‐641.
Motwani MP, Flint JD, De Maeyer RP, et al. Novel translational model of resolving inflammation triggered by UV‐killed E. Coli. J Pathol Clin Res. 2016;2(3):154‐165.
Hijma HJ, Moss LM, Gal P, et al. Challenging the challenge: a randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single‐dose LPS administration, as a potential model for inflammatory pain in early‐phase drug development. Brain Behav Immun. 2020;88:515‐528.
ClinicalTrials.gov NCT03244462. Food effect, oral & intravenous pharmacokinetics and absolute bioavailability of BAY1834845 including drug–drug interaction with methotrexate. 2017. Accessed November 22, 2022. https://clinicaltrials.gov/ct2/show/NCT03244462
Lauharanta J, Paravicini U. Plasma and suction blister fluid levels of etretinate and its main metabolite during treatment of psoriasis. Arch Dermatol Res. 1982;272(1–2):147‐149.
Mazzei T, Novelli A, Esposito S, Periti P. New insight into the clinical pharmacokinetics of cefaclor: tissue penetration. J Chemother. 2000;12(1):53‐62.
Dragatin C, Polus F, Bodenlenz M, et al. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp Dermatol. 2016;25(2):157‐159.
Dudhgaonkar S, Ranade S, Nagar J, et al. Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity. J Immunol. 2017;198(3):1308‐1319.
Assil S, Buters TP, Hameeteman PW, et al. Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model. Front Immunol. 2023;14:1197650.
Dillingh MR, van Poelgeest EP, Malone KE, et al. Characterization of inflammation and immune cell modulation induced by low‐dose LPS administration to healthy volunteers. J Inflamm. 2014;11:28.
Brooks D, Barr LC, Wiscombe S, McAuley DF, Simpson AJ, Rostron AJ. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation. Eur Respir J. 2020;56(1):1901298.
de Kruif MD, Lemaire LC, Giebelen IA, et al. Prednisolone dose‐dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178(3):1845‐1851.
Winkler A, Sun W, De S, et al. The interleukin‐1 receptor‐associated kinase 4 inhibitor PF‐06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheum. 2021;73(12):2206‐2218.
Ackerman L, Acloque G, Bacchelli S, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023;29(12):3127‐3136.
Buters TP, Hameeteman PW, Jansen IME, et al. Clinical, cellular, and molecular effects of corticosteroids on the response to intradermal lipopolysaccharide administration in healthy volunteers. Clin Pharmacol Ther. 2022;111(4):964‐971.
ClinicalTrials.gov NCT05656911. A study to learn how well the study treatment zabedosertib (BAY1834845) works and how safe it is compared to placebo in adult participants with moderate‐to‐severe atopic dermatitis (Damask). 2023. Accessed October 31, 2023. https://clinicaltrials.gov/study/NCT05656911